Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Business Times Journal.
Press releases published on May 14, 2025
Snail, Inc. Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 14, 2025
CULVER CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today announced financial results for its first …
dLocal Reports 2025 First Quarter Financial Results
GlobeNewswire
·
May 14, 2025
Record highs across key financial and operational metrics. TPV milestone of US$8 billion, +53% YoY and +5% QoQ. In constant currency, TPV increased +72% YoY. Revenue and gross profit record highs of US$217 million and US$85 million. Continued geographic …
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
GlobeNewswire
·
May 14, 2025
BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial …
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
GlobeNewswire
·
May 14, 2025
First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million …
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim …
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Tenax …
Rekor Systems Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 14, 2025
Gross Revenue: Quarterly gross revenue of $9.2 million, representing a 6% decrease from $9.8 million in 2024. Improved Adjusted EBITDA: Substantially narrowed Adjusted EBITDA loss from $9.4 million in Q1 2024 to $7.4 million in Q1 2025, underscoring …
Reliance Global Group Reports 2025 First Quarter Results and Provides Business Update
GlobeNewswire
·
May 14, 2025
LAKEWOOD, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (Nasdaq: RELI) (“Reliance”, “we” or the “Company”) today provided a business update and reported financial results for the quarter ended March 31, 2025. “We are pleased to begin …
Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine
GlobeNewswire
·
May 14, 2025
Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral shedding Machine learning analyses identified statistically significant correlates of protection and will be incorporated into the development of Vaxart’s …
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
GlobeNewswire
·
May 14, 2025
SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of …
Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia
GlobeNewswire
·
May 14, 2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the Phase I COVALENT-103 trial of BMF-500 in …
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
May 14, 2025
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results …
Sultan Center Food Products Company: A Legacy of Innovation and Commitment to Quality
EIN Presswire
·
May 14, 2025
KUWAIT, May 14, 2025 /EINPresswire.com/ -- Sultan Center Food Products Company (Sultan), a pioneer in the grocery retail industry, has become a well-known name in the region since opening its first store in Kuwait in 1981. Today, Sultan operates a …
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 14, 2025
Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment …
TMC Provides First Quarter 2025 Corporate Update
GlobeNewswire
·
May 14, 2025
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or “the Company”), a leading explorer of the world’s largest undeveloped resource of critical metals essential to energy, defense, manufacturing, and infrastructure …
Galapagos kondigt mondelinge presentaties aan tijdens EHA en ICML 2025 met veelbelovende nieuwe resultaten uit de ATALANTA-1 studie met CAR-T kandidaat GLPG5101
GlobeNewswire
·
May 14, 2025
Mechelen, België; 14 mei 2025, 22:01 CET; Galapagos NV (Euronext …
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
GlobeNewswire
·
May 14, 2025
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort …
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 14, 2025
PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on May 9, 2025, the compensation committee …
Usio Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 14, 2025
Record First Quarter Revenues of $22.0 million Total payment dollars processed through all payment channels up 34% versus the prior year period SAN ANTONIO, May 14, 2025 (GLOBE NEWSWIRE) -- Usio, Inc. (Nasdaq: USIO), a leading FinTech company that …
Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award
GlobeNewswire
·
May 14, 2025
LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is pleased to announce that it is a Colorado Top Workplaces 2025 Winner. The Top Workplaces program has an 18-year history of …